Carbide-derived carbon (CDC), also known as tunable nanoporous carbon, is the common term for carbon materials derived from carbide precursors, such as binary (e.g. SiC, TiC), or ternary carbides, also known as MAX phases (e.g., Ti2AlC, Ti3SiC2). CDCs have also been derived from polymer-derived ceramics such as Si-O-C or Ti-C, and carbonitrides, such as Si-N-C. CDCs can occur in various structures, ranging from amorphous to crystalline carbon, from sp2- to sp3-bonded, and from highly porous to fully dense. Among others, the following carbon structures have been derived from carbide precursors: micro- and mesoporous carbon, amorphous carbon, carbon nanotubes, onion-like carbon, nanocrystalline diamond, graphene, and graphite. Among carbon materials, microporous CDCs exhibit some of the highest reported specific surface areas (up to more than 3000 m2/g). By varying the type of the precursor and the CDC synthesis conditions, microporous and mesoporous structures with controllable average pore size and pore size distributions can be produced. Depending on the precursor and the synthesis conditions, the average pore size control can be applied at sub-Angstrom accuracy. This ability to precisely tune the size and shapes of pores makes CDCs attractive for selective sorption and storage of liquids and gases (e.g., hydrogen, methane, CO2) and the high electric conductivity and electrochemical stability allows these structures to be effectively implemented in electrical energy storage and capacitive water desalinization.
The production of SiCl4 by high temperature reaction of Chlorine gas with Silicon Carbide was first patented in 1918 by Otis Hutchins, with the process further optimized for higher yields in 1956. The solid porous carbon product was initially regarded as a waste byproduct until its properties and potential applications were investigated in more detail in 1959 by Walter Mohun. Research was carried out in the 1960-1980s mostly by Russian scientists on the synthesis of CDC via halogen treatment, while hydrothermal treatment was explored as an alternative route to derive CDCs in the 1990s.